Logo image of RX.CA

BIOSYENT INC (RX.CA) Stock Overview

Canada - TSX-V:RX - CA0906901081 - Common Stock

11.2 CAD
-0.01 (-0.09%)
Last: 10/24/2025, 7:00:00 PM

RX.CA Key Statistics, Chart & Performance

Key Statistics
Market Cap128.58M
Revenue(TTM)39.51M
Net Income(TTM)8.26M
Shares11.48M
Float7.84M
52 Week High12.49
52 Week Low9.2
Yearly Dividend0.18
Dividend Yield1.74%
EPS(TTM)0.62
PE18.06
Fwd PE12.62
Earnings (Next)11-13 2025-11-13
IPO1981-05-22
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


RX.CA short term performance overview.The bars show the price performance of RX.CA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 2 -2 4 -4 6

RX.CA long term performance overview.The bars show the price performance of RX.CA in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 40 60

The current stock price of RX.CA is 11.2 CAD. In the past month the price decreased by -5.17%. In the past year, price decreased by -1.58%.

BIOSYENT INC / RX Daily stock chart

RX.CA Latest News, Press Relases and Analysis

RX.CA Competitors/Peers

The largest stocks on the Canadian markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
BHC.CA BAUSCH HEALTH COS INC 1.64 3.22B
TLRY.CA TILRAY BRANDS INC N/A 2.34B
CRON.CA CRONOS GROUP INC 50.57 1.36B
DHT-UN.CA DRI HEALTHCARE TRUST 7.05 836.13M
WEED.CA CANOPY GROWTH CORP N/A 642.67M
DHT-U.CA DRI HEALTHCARE TRUST 4.98 591.08M
GUD.CA KNIGHT THERAPEUTICS INC N/A 581.13M
TSND.CA TERRASCEND CORP N/A 417.81M
ACB.CA AURORA CANNABIS INC N/A 412.88M
HITI.CA HIGH TIDE INC N/A 405.93M
CPH.CA CIPHER PHARMACEUTICALS INC 22.64 366.89M
OGI.CA ORGANIGRAM GLOBAL INC N/A 331.80M

About RX.CA

Company Profile

RX logo image BioSyent, Inc. is a specialty pharmaceutical company, which engages in the development of pharmaceutical and healthcare products. The company is headquartered in Mississauga, Ontario. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., sources, acquires or in-licenses and further develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary, operates the Company’s business marketing biologically and health friendly non-chemical insecticides. The Company’s products include Combogesic, Cathejell, FeraMAX Pd Therapeutic 150, FeraMAX Pd Maintenance 45, FeraMAX Pd Powder 15, Gelclair, Inofolic, Proktis-M, RepaGyn, and Tibella. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia. FeraMAX Pd Maintenance 45 is a chewable supplement with iron plus vitamin B12 and vitamin C for the prevention of iron deficiency anemia.

Company Info

BIOSYENT INC

2476 Argentia Road, Suite 402

Mississauga ONTARIO L5N 6M1 CA

CEO: Rene Goehrum

Employees: 0

RX Company Website

RX Investor Relations

Phone: 18884390013

BIOSYENT INC / RX.CA FAQ

What does RX do?

BioSyent, Inc. is a specialty pharmaceutical company, which engages in the development of pharmaceutical and healthcare products. The company is headquartered in Mississauga, Ontario. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., sources, acquires or in-licenses and further develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary, operates the Company’s business marketing biologically and health friendly non-chemical insecticides. The Company’s products include Combogesic, Cathejell, FeraMAX Pd Therapeutic 150, FeraMAX Pd Maintenance 45, FeraMAX Pd Powder 15, Gelclair, Inofolic, Proktis-M, RepaGyn, and Tibella. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia. FeraMAX Pd Maintenance 45 is a chewable supplement with iron plus vitamin B12 and vitamin C for the prevention of iron deficiency anemia.


What is the stock price of BIOSYENT INC today?

The current stock price of RX.CA is 11.2 CAD. The price decreased by -0.09% in the last trading session.


Does RX stock pay dividends?

BIOSYENT INC (RX.CA) has a dividend yield of 1.74%. The yearly dividend amount is currently 0.18.


How is the ChartMill rating for BIOSYENT INC?

RX.CA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 8 out of 10.


How is the valuation of BIOSYENT INC (RX.CA) based on its PE ratio?

The PE ratio for BIOSYENT INC (RX.CA) is 18.06. This is based on the reported non-GAAP earnings per share of 0.62 and the current share price of 11.2 CAD.


Can you provide the upcoming earnings date for BIOSYENT INC?

BIOSYENT INC (RX.CA) will report earnings on 2025-11-13.


RX.CA Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

RX.CA Fundamental Analysis

ChartMill assigns a fundamental rating of 8 / 10 to RX.CA. Both the health and profitability get an excellent rating, making RX.CA a very profitable company, without any liquidiy or solvency issues.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

RX.CA Financial Highlights

Over the last trailing twelve months RX.CA reported a non-GAAP Earnings per Share(EPS) of 0.62. The EPS increased by 18.57% compared to the year before.


Industry RankSector Rank
PM (TTM) 20.9%
ROA 18.99%
ROE 21.97%
Debt/Equity 0.02
Chartmill High Growth Momentum
EPS Q2Q%30.97%
Sales Q2Q%13.8%
EPS 1Y (TTM)18.57%
Revenue 1Y (TTM)16.82%

RX.CA Forecast & Estimates

7 analysts have analysed RX.CA and the average price target is 13.26 CAD. This implies a price increase of 18.39% is expected in the next year compared to the current price of 11.2.

For the next year, analysts expect an EPS growth of 20.96% and a revenue growth 17.51% for RX.CA


Analysts
Analysts82.86
Price Target13.26 (18.39%)
EPS Next Y20.96%
Revenue Next Year17.51%

RX.CA Ownership

Ownership
Inst Owners3.82%
Ins Owners17.84%
Short Float %N/A
Short RatioN/A